| Name | Title | Contact Details |
|---|
Envigo provides essential products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations.
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention of counterfeiting and diversion. We have manufacturing facilities in Hawaii, engineering offices in California, and business development offices in Pennsylvania, Texas and Hong Kong. TruTag`s early technology research was funded in part by the U.S. Army Medical Research division. The company is supported by venture capital firms and strategic corporate investors.
Sydnexis Inc. is a clinical stage biopharmaceutical company based in San Diego. They are currently evaluating their patented eyedrop formulation, SYD 101, in a Phase 3 clinical trial to decrease myopia progression in children.
Everest Clinical Research ("Everest") is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today.
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.